308 related articles for article (PubMed ID: 29754725)
1. [Time in therapeutic range (TTR) and follow-up of patients on vitamin K antagonist: A cohort analysis].
Valdelièvre E; Quéré I; Caré B; Laroche JP; Schved JF
J Med Vasc; 2018 May; 43(3):155-162. PubMed ID: 29754725
[TBL] [Abstract][Full Text] [Related]
2. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
[TBL] [Abstract][Full Text] [Related]
3. Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study.
Sawicka-Powierza J; Buczkowski K; Chlabicz S; Gugnowski Z; Powierza K; Ołtarzewska AM
Kardiol Pol; 2018; 76(4):764-769. PubMed ID: 29313558
[TBL] [Abstract][Full Text] [Related]
4. Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol.
Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Marín F; Lip GYH
Clin Ther; 2018 Jan; 40(1):114-122. PubMed ID: 29275065
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
[TBL] [Abstract][Full Text] [Related]
6. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.
Haas S; Ten Cate H; Accetta G; Angchaisuksiri P; Bassand JP; Camm AJ; Corbalan R; Darius H; Fitzmaurice DA; Goldhaber SZ; Goto S; Jacobson B; Kayani G; Mantovani LG; Misselwitz F; Pieper K; Schellong SM; Stepinska J; Turpie AG; van Eickels M; Kakkar AK;
PLoS One; 2016; 11(10):e0164076. PubMed ID: 27792741
[TBL] [Abstract][Full Text] [Related]
7. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
8. Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients.
Lafarge L; Khayi F; Bel-Kamel A; Charhon N; Sarfati L; Falquet B; Ducher M; Bourguignon L
Drugs Aging; 2018 Jun; 35(6):569-574. PubMed ID: 29882202
[TBL] [Abstract][Full Text] [Related]
9. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry.
Le Heuzey JY; Ammentorp B; Darius H; De Caterina R; Schilling RJ; Schmitt J; Zamorano JL; Kirchhof P
Thromb Haemost; 2014 May; 111(5):833-41. PubMed ID: 24651882
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment.
Gorzelak-Pabiś P; Zyzak S; Krewko Ł; Broncel M
Pol Arch Med Wewn; 2016 Aug; 126(7-8):494-501. PubMed ID: 27511466
[TBL] [Abstract][Full Text] [Related]
12. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.
Esteve-Pastor MA; Rivera-Caravaca JM; Roldán-Rabadán I; Roldán V; Muñiz J; Raña-Míguez P; Ruiz-Ortiz M; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
Europace; 2018 Sep; 20(9):1435-1441. PubMed ID: 29095971
[TBL] [Abstract][Full Text] [Related]
13. Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
Kooistra HA; Gebel M; Sahin K; Lensing AW; Meijer K
Thromb Haemost; 2015 Nov; 114(6):1136-43. PubMed ID: 26224199
[TBL] [Abstract][Full Text] [Related]
14. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
[TBL] [Abstract][Full Text] [Related]
15. A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants.
Carrier M; Kimpton M; Wells PS; Langlois N; Kherani S; Le Gal G
Blood Coagul Fibrinolysis; 2014 Dec; 25(8):812-5. PubMed ID: 24914740
[TBL] [Abstract][Full Text] [Related]
16. SAMe-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events.
Pivatto Junior F; Scheffel RS; Ries L; Wolkind RR; Marobin R; Barkan SS; Amon LC; Biolo A
Arq Bras Cardiol; 2017 Apr; 108(4):290-296. PubMed ID: 28538758
[TBL] [Abstract][Full Text] [Related]
17. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Ansell J; Hirsh J; Poller L; Bussey H; Jacobson A; Hylek E
Chest; 2004 Sep; 126(3 Suppl):204S-233S. PubMed ID: 15383473
[TBL] [Abstract][Full Text] [Related]
18. Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control.
Bonde AN; Staerk L; Lee CJ; Vinding NE; Bang CN; Torp-Pedersen C; Gislason G; Lip GYH; Olesen JB
J Am Coll Cardiol; 2018 Sep; 72(12):1357-1365. PubMed ID: 30213328
[TBL] [Abstract][Full Text] [Related]
19. Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists.
Pignatelli P; Pastori D; Vicario T; Bucci T; Del Ben M; Russo R; Tanzilli A; Nardoni ML; Bartimoccia S; Nocella C; Ferro D; Saliola M; Cangemi R; Lip GY; Violi F
Europace; 2015 Aug; 17(8):1223-8. PubMed ID: 25995397
[TBL] [Abstract][Full Text] [Related]
20. Relation of the SAMe-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials.
Proietti M; Lane DA; Lip GY
Int J Cardiol; 2016 Aug; 216():168-72. PubMed ID: 27156060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
